. The company’s pipeline features 4 scientific-stage therapies. Its most Highly developed drug applicant is ROS1 inhibitor taletrectinib for managing lung cancer. Nuvation is finishing two phase 2 pivotal studies on taletrectinib. The high-risk nature of such stocks means they might experience significant price swings, usually driven by market https://financefeeds.com/allegations-of-token-manipulation/